What is William Blair's Estimate for DNTH FY2025 Earnings?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at William Blair issued their FY2025 EPS estimates for shares of Dianthus Therapeutics in a research note issued on Wednesday, July 2nd. William Blair analyst M. Minter anticipates that the company will earn ($3.26) per share for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. William Blair also issued estimates for Dianthus Therapeutics' FY2026 earnings at ($3.00) EPS, FY2027 earnings at ($2.99) EPS, FY2028 earnings at ($3.11) EPS and FY2029 earnings at ($3.81) EPS.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.81 million.

A number of other analysts have also recently weighed in on DNTH. Robert W. Baird decreased their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Guggenheim restated a "buy" rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of "Buy" and an average price target of $53.00.

Dianthus Therapeutics Trading Down 3.2%

Shares of NASDAQ DNTH traded down $0.60 during mid-day trading on Friday, reaching $18.25. The company had a trading volume of 215,078 shares, compared to its average volume of 264,657. The firm has a 50 day simple moving average of $18.85 and a two-hundred day simple moving average of $20.42. The stock has a market cap of $586.92 million, a P/E ratio of -6.34 and a beta of 1.38. Dianthus Therapeutics has a 52-week low of $13.37 and a 52-week high of $32.27.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new position in Dianthus Therapeutics during the fourth quarter worth about $33,000. US Bancorp DE raised its position in shares of Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock worth $29,000 after purchasing an additional 1,510 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in Dianthus Therapeutics in the 4th quarter valued at approximately $59,000. GAMMA Investing LLC grew its holdings in Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after buying an additional 3,758 shares during the last quarter. Finally, AlphaQuest LLC grew its holdings in Dianthus Therapeutics by 273.1% during the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after buying an additional 3,072 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.